How Much Intellectual Property Protection Do the Newest (and Coolest) Biotechnologies Get Internationally?+

By Weisfeld, Alix | Chicago Journal of International Law, Winter 2006 | Go to article overview

How Much Intellectual Property Protection Do the Newest (and Coolest) Biotechnologies Get Internationally?+


Weisfeld, Alix, Chicago Journal of International Law


Since the completion of the Human Genome Project in 2000, we are already seeing changes in health care. As we better understand the genetic basis of disease, we are able to target therapies to these root causes of disease. This paper will consider how two nascent areas of genetic medicine, pharmacogenetics and biologies, interact with international intellectual property ("IP") law. Neither of these areas fits comfortably in the traditional intellectual property model we use for pharmaceuticals. Due to their growing importance, however, the implications for international law concerning these advances are great.

The first section of the paper will give a background on what biologies and pharmacogenetics are. section II will examine regulatory protections given to pharmaceuticals both nationally and abroad. section III will consider what patent protections have been awarded to pharmaceuticals in the US and internationally. section IV concludes.

I. WHAT ARE BIOLOGICS AND PHARMACOGENETICS, AND WHO CARES?

A. WHAT ARE BIOLOGICS?

Biologies are drugs manufactured through biological processes. They are some of the hottest drugs around today and are certainly among the most expensive. Unlike chemical drugs, which typically are comprised of several hundred atoms, biologies are complex proteins that contain thousands of atoms folded over onto themselves.1 This structural complexity makes them much more difficult to create, and consequently to duplicate.

Some biologies act as catalysts for biologic processes that subsequently occur in the patient's body. A major example of this type of biologic is insulin. Diabetics either do not make insulin properly or are desensitized to it, but bacteria can be manipulated to produce human insulin when injected with the human gene for insulin. Likewise, many vaccines are created by the biologic process.

Other biologies, called monoclonal antibodies, interfere with the adhesion of certain compounds to cell receptors. For example, rituximab is the generic name for a monoclonal antibody that adheres to a particular molecule found on the surface of the cells of abnormal B-cell lymphocytes that often occur in nonHodgkin's lymphoma. Rituximab binds to this molecule and causes the body to destroy the cancerous cell. In addition to treating cancer, monoclonal antibodies are useful for treating anemia, diabetes, hepatitis, and multiple sclerosis, and are an effective growth hormone (which is often prescribed to prevent AIDS-related wasting disease).

Because they are proteins and not chemicals, biologies must be manufactured through living organisms. This makes them expensive to produce, and consequently expensive for consumers.2 In 2001, 25 percent of all increases in US hospital expenditures (which themselves account for 30 percent of all medical expenses) were attributable to four products, three of which were biologies (epoetin alfa, infliximab, and rituximab).3 Biologic sales in the US may top $56 billion in 2006.4

B. WHAT ARE PHARMACOGENETICS?

The term pharmacogenetics (commonly called "personalized medicine" in the lay press), describes the process of targeting drug therapies to individual patients' genetic make-up. Unlike biologies and chemical compounds, it is not a drug product per se.

Pharmacogenetics aims to improve pharmaceutical safety and efficacy based on genetic variation. This variation can occur in two ways. The first way pharmacogenetics can be applied is to attack irregularities within the disease itself (for example, drug-resistant strains of HIV or differences in tumor type). A prominent example is Herceptin, which can effectively treat breast cancer, but only works in about 25 percent of all women with the disease. Patients need to be genetically screened before they are prescribed the medicine because there is no other way to distinguish responders from non-responders.

The second way pharmacogenetics can be effective is when a patient's genetic make-up affects interaction with a drug. …

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

How Much Intellectual Property Protection Do the Newest (and Coolest) Biotechnologies Get Internationally?+
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.